Tsung-Ru Wu1, Tsung-Teng Huang2, Jan Martel3, Jian-Ching Liau4, Chen-Yaw Chiu5, Yann-Lii Leu6, Wei-Ting Jian4, I-Te Chang4, Chia-Chen Lu7, David M Ojcius8, Yun-Fei Ko9, Hsin-Chih Lai10, John D Young11. 1. Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan; Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan. 2. Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan; Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan; Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Research Center of Bacterial Pathogenesis, Chang Gung University, Taoyuan 33302, Taiwan. 3. Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Laboratory of Nanomaterials, Chang Gung University, Taoyuan 33302, Taiwan. 4. Chang Gung Biotechnology Corporation, Taipei 10508, Taiwan. 5. Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City 24301, Taiwan. 6. Graduate Institute of Natural Products, Chang Gung University, Taoyuan 33302, Taiwan. 7. Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City 24205, Taiwan. 8. Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA 94103, United States. 9. Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Biotechnology Corporation, Taipei 10508, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City 24301, Taiwan. 10. Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan; Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan; Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Research Center of Bacterial Pathogenesis, Chang Gung University, Taoyuan 33302, Taiwan; Research Center for Industry of Human Ecology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan; Graduate Institute of Health Industry and Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan. Electronic address: hclai@mail.cgu.edu.tw. 11. Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Immunology Consortium, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33302, Taiwan; Laboratory of Nanomaterials, Chang Gung University, Taoyuan 33302, Taiwan; Chang Gung Biotechnology Corporation, Taipei 10508, Taiwan; Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City 24301, Taiwan; Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, NY 10021, United States. Electronic address: jdyoung@mail.cgu.edu.tw.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: The medicinal mushroom Antrodia cinnamomea possesses anticancer properties but the active compounds responsible for these effects are mostly unknown. AIM OF THE STUDY: We aimed to identify novel A. cinnamomea compounds that produce cytotoxic effects on cancer cells. MATERIALS AND METHODS: Using ethanol extraction and chromatography, we isolated the lanostanoid compound lanosta-7,9(11),24-trien-3β,15α,21-triol (1) from cultured A. cinnamomea mycelium. Cytotoxicity and pro-apoptotic effects of compound 1 were evaluated using the MTS assay and flow cytometry analysis, respectively. RESULTS: Compound 1 produced cytotoxic effects on the nasopharyngeal carcinoma cell lines TW02 and TW04, with IC50 values of 63.3 and 115.0μM, respectively. On the other hand, no cytotoxic effects were observed on non-tumorigenic nasopharyngeal epithelial cells (NP69). In addition, compound 1 induced apoptosis in TW02 and TW04 cells as revealed by flow cytometry analysis. CONCLUSIONS: Our results demonstrate for the first time the presence of pinicolol B in A. cinnamomea mycelium and suggest that this compound may contribute to the anticancer effects of A. cinnamomea.
ETHNOPHARMACOLOGICAL RELEVANCE: The medicinal mushroomAntrodia cinnamomea possesses anticancer properties but the active compounds responsible for these effects are mostly unknown. AIM OF THE STUDY: We aimed to identify novel A. cinnamomea compounds that produce cytotoxic effects on cancer cells. MATERIALS AND METHODS: Using ethanol extraction and chromatography, we isolated the lanostanoid compound lanosta-7,9(11),24-trien-3β,15α,21-triol (1) from cultured A. cinnamomea mycelium. Cytotoxicity and pro-apoptotic effects of compound 1 were evaluated using the MTS assay and flow cytometry analysis, respectively. RESULTS: Compound 1 produced cytotoxic effects on the nasopharyngeal carcinoma cell lines TW02 and TW04, with IC50 values of 63.3 and 115.0μM, respectively. On the other hand, no cytotoxic effects were observed on non-tumorigenic nasopharyngeal epithelial cells (NP69). In addition, compound 1 induced apoptosis in TW02 and TW04 cells as revealed by flow cytometry analysis. CONCLUSIONS: Our results demonstrate for the first time the presence of pinicolol B in A. cinnamomea mycelium and suggest that this compound may contribute to the anticancer effects of A. cinnamomea.